Xencor Collaboration with MD Anderson

Gunderson Dettmer represented client Xencor, a clinical-stage biopharmaceutical company, in its collaboration agreement with MD Anderson to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.

In the announcement of the transaction, SVP and chief science officer of Xencor John Desjarlais said, “Xencor’s modular antibody engineering platform enables the rapid generation of XmAb bispecific antibodies, and our research collaboration with MD Anderson will further expand the use of our technology to explore novel therapeutic targets, which could result in the creation of new therapies for patients with cancer.”

The Gunderson deal team was led by Brendan McCarthy.